0923 tau miss
selvanegra / iStock / Getty Images Plus.

Product Development

The road ahead for the tau hypothesis of Alzheimer’s disease

First tau data — delivered by Genentech — put antibody therapies on shaky ground

First tau data — delivered by Genentech — put antibody therapies on shaky ground.

Sep 24, 2020 | 1:42 AM GMT

The Phase II miss of the first tau antibody to reach that stage continue the tradition in Alzheimer’s disease of bad news with hard-to-interpret ramifications for the target. At a minimum, the data call into question the use of antibodies in attacking a target that primarily resides inside cells.

At least nine anti-tau therapies have begun clinical testing, and the protein has gained status as the next big target, and maybe hope, behind amyloid (see “Is Tau the New Amyloid?”).

Six of those therapies are antibodies.

Semorinemab from AC Immune S.A.

Read the full 1360 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE